scfv

Antibody fragmentation generates Fab, F(ab’)2, and scFv. Biointron shows how fragments expand antibody applications in imaging, diagnostics, and therapeutics.

scFvs combine compact design with strong binding. Biointron explores their history, therapeutic applications, and role in diagnostics and research innovation.

Antibody drugs for diabetes typically target specific molecules involved in the regulation of blood sugar levels or the immune response against insulin-producing cells, or specific hormones or receptors involved in glucose metabolism. For instance, teplizumab (Tzield), targets CD3 on T cells, thus deactivating immune cells which attack β-cells.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.